Hypertrophic Cardiomyopathy Differential Diagnoses

1. [Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, et al. J Am Coll Cardiol. 2011 Dec 13. 58(25):e212-60. [QxMD MEDLINE Link].

2. Maron BJ, Peterson EE, Maron MS, Peterson JE. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study. Am J Cardiol. 1994 Mar 15. 73(8):577-80. [QxMD MEDLINE Link].

3. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995 Aug 15. 92(4):785-9. [QxMD MEDLINE Link].

4. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA. 2002 Mar 13. 287(10):1308-20. [QxMD MEDLINE Link].

5. Elliott PM, Gimeno JR, Thaman R, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart. 2006 Jun. 92(6):785-91. [QxMD MEDLINE Link].

6. Minami Y, Kajimoto K, Terajima Y, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2011 Jun 7. 57(23):2346-55. [QxMD MEDLINE Link].

7. DeRose JJ Jr, Banas JS Jr, Winters SL. Current perspectives on sudden cardiac death in hypertrophic cardiomyopathy. Prog Cardiovasc Dis. 1994 May-Jun. 36(6):475-84. [QxMD MEDLINE Link].

8. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982 Jun. 65(7):1388-94. [QxMD MEDLINE Link].

9. [Guideline] Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014 Oct 14. 35(39):2733-79. [QxMD MEDLINE Link]. [Full Text].

10. Aguiar Rosa S, Thomas B, Fiarresga A, et al. The impact of ischemia assessed by magnetic resonance on functional, arrhythmic, and imaging features of hypertrophic cardiomyopathy. Front Cardiovasc Med. 2021. 8:761860. [QxMD MEDLINE Link]. [Full Text].

11. Soor GS, Luk A, Ahn E, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. 2009 Mar. 62(3):226-35. [QxMD MEDLINE Link].

12. Verlinden NJ, Coons JC. Disopyramide for hypertrophic cardiomyopathy: a pragmatic reappraisal of an old drug. Pharmacotherapy. 2015 Dec. 35(12):1164-72. [QxMD MEDLINE Link].

13. Boggs W. Stepwise antihypertensive therapy effective in hypertrophic cardiomyopathy. Medscape Medical News. February 4, 2013. Available at http://www.medscape.com/viewarticle/778707. Accessed: February 26, 2013.

14. Argulian E, Messerli FH, Aziz EF, et al. Antihypertensive therapy in hypertrophic cardiomyopathy. Am J Cardiol. 2013 Apr 1. 111(7):1040-5. [QxMD MEDLINE Link].

15. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021 Jun 26. 397 (10293):2467-75. [QxMD MEDLINE Link].

16. Desai N, Xie J, Wang Y, et al. Projecting the long-term clinical value of mavacamten for the treatment of obstructive hypertrophic cardiomyopathy in the United States: an assessment of net health benefit. Clin Ther. 2022 Jan. 44 (1):52-66.e2. [QxMD MEDLINE Link]. [Full Text].

17. Schaff HV, Dearani JA, Ommen SR, Sorajja P, Nishimura RA. Expanding the indications for septal myectomy in patients with hypertrophic cardiomyopathy: Results of operation in patients with latent obstruction. J Thorac Cardiovasc Surg. 2012 Feb. 143(2):303-9. [QxMD MEDLINE Link].

18. Panaich SS, Badheka AO, Chothani A, et al. Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). Am J Cardiol. 2014 Nov 1. 114(9):1390-5. [QxMD MEDLINE Link].

19. Vriesendorp PA, Schinkel AF, Soliman OI, et al. Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2015 Mar 1. 115(5):670-5. [QxMD MEDLINE Link].

20. Singh K, Qutub M, Carson K, Hibbert B, Glover C. A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy. Catheter Cardiovasc Interv. 2016 Jul. 88(1):107-15. [QxMD MEDLINE Link].

21. Cui H, Schaff HV, Wang S, Lahr BD, Rowin EJ, Rastegar H, et al. Survival following alcohol septal ablation or septal myectomy for patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022 May 3. 79 (17):1647-55. [QxMD MEDLINE Link].

22. [Guideline] Gersh BJ, Maron BJ, Bonow RO, et al, for the ACCF/AHA, AATS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011 Dec 13. 124(24):2761-96. [QxMD MEDLINE Link].

23. Qintar M, Morad A, Alhawasli H, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev. 2012 May 16. 5:CD008523. [QxMD MEDLINE Link].

24. Hagege AA, Desnos M. New trends in treatment of hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2009 May. 102(5):441-7. [QxMD MEDLINE Link].

25. Jassal DS, Neilan TG, Fifer MA, et al. Sustained improvement in left ventricular diastolic function after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Eur Heart J. 2006 Aug. 27(15):1805-10. [QxMD MEDLINE Link].

26. Streit S, Walpoth N, Windecker S, Meier B, Hess O. Is alcohol ablation of the septum associated with recurrent tachyarrhythmias?. Swiss Med Wkly. 2007 Dec 1. 137(47-48):660-8. [QxMD MEDLINE Link].

27. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart. 2009 May. 95 (9):709-14. [QxMD MEDLINE Link].

28. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol. 2014 Jul 1. 63 (25 Pt A):2831-9. [QxMD MEDLINE Link].

29. Ashikhmina E, Farber MK, Mizuguchi KA. Parturients with hypertrophic cardiomyopathy: case series and review of pregnancy outcomes and anesthetic management of labor and delivery. Int J Obstet Anesth. 2015 Nov. 24(4):344-55. [QxMD MEDLINE Link].

30. [Guideline] Federal Motor Carrier Safety Administration (FMCSA). Recommendations of the medical expert panel. (See section 9: CMV drivers with cardiomyopathy). Available at https://www.fmcsa.dot.gov/regulations/medical/recommendations-medical-expert-panel. Updated August 28, 2015; Accessed: December 22, 2015.

31. Federal Aviation Administration. Guide for aviation medical examiners. Decision considerations - aerospace medical dispositions. Item 36. Heart. Available at https://www.faa.gov/about/office_org/headquarters_offices/avs/offices/aam/ame/guide/app_process/exam_tech/item36/amd/. Modified June 20, 2014; Accessed: December 22, 2015.

32. Maron BJ, Barry JA, Poole RS. Pilots, hypertrophic cardiomyopathy, and issues of aviation and public safety. Am J Cardiol. 2004 Feb 15. 93(4):441-4. [QxMD MEDLINE Link].

33. Pack C. Hypertrophic cardiomyopathy in a first-class airman. The Federal Air Surgeon's Medical Bulletin. Vol 51, no 2. Revised April 29, 2013. Accessed December 22, 2015. Available at https://www.faa.gov/other_visit/aviation_industry/designees_delegations/designee_types/ame/fasmb/media/201302.pdf.

34. Federal Aviation Administration. Guide for aviation medical examiners. Decision considerations - aerospace medical dispositions. Item 36. Heart - other cardiac conditions. Available at http://www.faa.gov/about/office_org/headquarters_offices/avs/offices/aam/ame/guide/app_process/exam_tech/item36/amd/occ/. Modified June 20, 2014; Accessed: December 22, 2015.

35. Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol. 1994 Oct. 24(4):880-5. [QxMD MEDLINE Link].

36. Thompson PD, Franklin BA, Balady GJ, Blair SN, Corrado D, Estes NA 3rd, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation. 2007 May 1. 115(17):2358-68. [QxMD MEDLINE Link].

37. [Guideline] Gillis AM, Russo AM, Ellenbogen KA, et al, for the Heart Rhythm Society, American College of Cardiology Foundation. HRS/ACCF expert consensus statement on pacemaker device and mode selection. Developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. Heart Rhythm. 2012 Aug. 9(8):1344-65. [QxMD MEDLINE Link].

38. [Guideline] Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013 Aug. 34(29):2281-329. [QxMD MEDLINE Link]. [Full Text].

39. [Guideline] Maron BJ, Udelson JE, Bonow RO, et al. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 3: Hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy and other cardiomyopathies, and myocarditis: a scientific statement from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2015 Dec 1. 66(21):2362-71. [QxMD MEDLINE Link]. [Full Text].

40. Counihan PJ, McKenna WJ. Low-dose amiodarone for the treatment of arrhythmias in hypertrophic cardiomyopathy. J Clin Pharmacol. 1989 May. 29(5):436-8. [QxMD MEDLINE Link].

41. Fananapazir L, Leon MB, Bonow RO, et al. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 1991 Jan 15. 67(2):169-74. [QxMD MEDLINE Link].

42. Ly HQ, Greiss I, Talakic M, et al. Sudden death and hypertrophic cardiomyopathy: a review. Can J Cardiol. 2005 Apr. 21(5):441-8. [QxMD MEDLINE Link].

43. Colombo MG, Botto N, Vittorini S, Paradossi U, Andreassi MG. Clinical utility of genetic tests for inherited hypertrophic and dilated cardiomyopathies. Cardiovasc Ultrasound. 2008 Dec 19. 6:62. [QxMD MEDLINE Link]. [Full Text].

44. Morimoto S. Sarcomeric proteins and inherited cardiomyopathies. Cardiovasc Res. 2008 Mar 1. 77(4):659-66. [QxMD MEDLINE Link].

45. Soor GS, Luk A, Ahn E, et al. Hypertrophic cardiomyopathy: current understanding and treatment objectives. J Clin Pathol. 2009 Mar. 62(3):226-35. [QxMD MEDLINE Link].

46. Van Driest SL, Ackerman MJ, Ommen SR, et al. Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation. 2002 Dec 10. 106(24):3085-90. [QxMD MEDLINE Link].

47. Musat D, Sherrid MV. Echocardiography in the treatment of hypertrophic cardiomyopathy. Anadolu Kardiyol Derg. 2006 Dec. 6 Suppl 2:18-26. [QxMD MEDLINE Link].

48. Peteiro J, Bouzas-Mosquera A, Fernandez X, et al. Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2012 Feb. 25(2):182-9. [QxMD MEDLINE Link].

49. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010 Sep 7. 56(11):875-87. [QxMD MEDLINE Link].

50. Gillinov AM. Updated guidelines for device-based therapy of cardiac rhythm abnormalities. J Thorac Cardiovasc Surg. 2012 Dec. 144(6):1285. [QxMD MEDLINE Link].

51. Topilski I, Sherez J, Keren G, Copperman I. Long-term effects of dual-chamber pacing with periodic echocardiographic evaluation of optimal atrioventricular delay in patients with hypertrophic cardiomyopathy >50 years of age. Am J Cardiol. 2006 Jun 15. 97(12):1769-75. [QxMD MEDLINE Link].

52. Galve E, Sambola A, Saldana G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart. 2010 Mar. 96(5):352-6. [QxMD MEDLINE Link].

53. Silva LA, Fernandez EA, Martinelli Filho M, et al. Cardiac pacing in hypertrophic cardiomyopathy: a cohort with 24 years of follow-up. Arq Bras Cardiol. 2008 Oct. 91(4):250-6, 274-80. [QxMD MEDLINE Link].

54. You JJ, Woo A, Ko DT, Cameron DA, Mihailovic A, Krahn M. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy. Am Heart J. 2007 Nov. 154(5):899-907. [QxMD MEDLINE Link].

55. Jensen MK, Prinz C, Horstkotte D, et al. Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile. Heart. 2013 Jul. 99(14):1012-7. [QxMD MEDLINE Link].

56. McKinney AM, Lohman BD, Sarikaya B, Benson M, Lee MS, Benson MT. Accuracy of routine fat-suppressed FLAIR and diffusion-weighted images in detecting clinically evident acute optic neuritis. Acta Radiol. 2013 May. 54(4):455-61. [QxMD MEDLINE Link].

57. Zhao DS, Shen Y, Zhang Q, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace. 2016 Apr. 18(4):508-20. [QxMD MEDLINE Link].

58. Goland S, van Hagen IM, Elbaz-Greener G, et al. Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). Eur Heart J. 2017 Sep 14. 38(35):2683-90. [QxMD MEDLINE Link].

59. Liebregts M, Vriesendorp PA, Ten Berg JM. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a word of endorsement. J Am Coll Cardiol. 2017 Jul 25. 70(4):481-8. [QxMD MEDLINE Link].

60. Hong JH, Schaff HV, Nishimura RA, et al. Mitral regurgitation in patients with hypertrophic obstructive cardiomyopathy: implications for concomitant valve procedures. J Am Coll Cardiol. 2016 Oct 4. 68(14):1497-504. [QxMD MEDLINE Link].

61. Hebl VB, Miranda WR, Ong KC, et al. The natural history of nonobstructive hypertrophic cardiomyopathy. Mayo Clin Proc. 2016 Mar. 91(3):279-87. [QxMD MEDLINE Link].

62. Semsarian C, Ingles J, Maron MS, Maron BJ. New Perspective on the prevalence of hypertrophyic cardiomyopathy. J Am Coll Cardiol. 2015. 65:1249-54.

63. Klettas D, Georgiopoulos G, Rizvi Q, Oikonomou D, Magkas N, Bhuva AN, et al. Echocardiographic and cardiac magnetic resonance imaging-derived strains in relation to late gadolinium enhancement in hypertrophic cardiomyopathy. Am J Cardiol. 2022 May 15. 171:132-9. [QxMD MEDLINE Link].

64. Bonaventura J, Norambuena P, Tomasov P, Jindrova D, Sediva H, Macek M Jr, et al. The utility of the Mayo Score for predicting the yield of genetic testing in patients with hypertrophic cardiomyopathy. Arch Med Sci. 2019 May. 15 (3):641-9. [QxMD MEDLINE Link]. [Full Text].

Sandy N Shah, DO, MBA, FACC, FACP, FACOI Cardiologist

Sandy N Shah, DO, MBA, FACC, FACP, FACOI is a member of the following medical societies: American College of Cardiology, American College of Osteopathic Internists, American College of Physicians, American Medical Association, American Osteopathic Association, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions

Disclosure: Nothing to disclose.

Arti N Shah, MD, MS, FACC, FACP, CEPS-AC, CEDS Assistant Professor of Medicine, Mount Sinai School of Medicine; Director of Electrophysiology, Elmhurst Hospital Center and Queens Hospital Center

Arti N Shah, MD, MS, FACC, FACP, CEPS-AC, CEDS is a member of the following medical societies: American Association of Cardiologists of Indian Origin, American College of Cardiology, American College of Physicians, American Heart Association, Cardiac Electrophysiology Society, European Heart Rhythm Society, European Society of Cardiology, Heart Rhythm Society, New York Academy of Medicine

Disclosure: Nothing to disclose.

Gyanendra K Sharma, MD, FACC, FASE Professor of Medicine and Radiology, Director, Adult Echocardiography Laboratory, Section of Cardiology, Medical College of Georgia at Augusta University

Gyanendra K Sharma, MD, FACC, FASE is a member of the following medical societies: American Association of Cardiologists of Indian Origin, American Association of Physicians of Indian Origin, American College of Cardiology, American Society of Echocardiography, Society for Cardiovascular Magnetic Resonance, Society of Cardiovascular Computed Tomography

Disclosure: Nothing to disclose.

Gary Edward Sander, MD, PhD, FACC, FAHA, FACP, FASH Professor of Medicine, Director of CME Programs, Team Leader, Root Cause Analysis, Tulane University Heart and Vascular Institute; Director of In-Patient Cardiology, Tulane Service, University Hospital; Visiting Physician, Medical Center of Louisiana at New Orleans; Faculty, Pennington Biomedical Research Institute, Louisiana State University; Professor, Tulane University School of Medicine

Gary Edward Sander, MD, PhD, FACC, FAHA, FACP, FASH is a member of the following medical societies: Alpha Omega Alpha, American Chemical Society, American College of Cardiology, American College of Chest Physicians, American College of Physicians, American Federation for Clinical Research, American Federation for Medical Research, American Heart Association, American Society for Pharmacology and Experimental Therapeutics, American Society of Hypertension,American Thoracic Society, Heart Failure Society of America, Louisiana State Medical Society, National Lipid Association, and Southern Society for Clinical Investigation

Disclosure: Forest Labs Honoraria Speaking and teaching

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article